CRISPR technology is barely six years old and has not been used in humans. Last year, a federal advisory panel approved a University of Pennsylvania proposal to use CRISPR to engineer immune cells to fight certain types of cancer, but the trial must still be approved by the U.S. Food and Drug Administration.